CN106822217B - Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis - Google Patents
Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis Download PDFInfo
- Publication number
- CN106822217B CN106822217B CN201710089659.2A CN201710089659A CN106822217B CN 106822217 B CN106822217 B CN 106822217B CN 201710089659 A CN201710089659 A CN 201710089659A CN 106822217 B CN106822217 B CN 106822217B
- Authority
- CN
- China
- Prior art keywords
- cranberry
- preventing
- dried powder
- medicine
- adenomatous polyposis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of cranberry freeze-dried powder in preparation of a medicine for preventing and treating familial adenomatous polyposis. The cranberry freeze-dried powder provided by the invention is used as a dietary supplement which can directly inhibit the growth of polyps, has a definite curative effect and no side effect, and has very important significance for clinical prevention and treatment of FAP, improvement of the life quality of patients and reduction of relapse. The invention provides a safe, effective and economical new method for preventing and treating FAP and sporadic intestinal polyp, and has wide application prospect.
Description
Technical Field
The invention relates to a new application of cranberry, in particular to an application of cranberry freeze-dried powder in preparation of a medicine for preventing and treating familial adenomatous polyposis.
Background
Familial Adenomatous Polyposis (FAP) is an autosomal dominant genetic disease characterized by multiple adenomatous polyposis of the digestive tract, the onset of which is primarily associated with Apc mutations. Due to the special genetic background of FAP, the FAP is frequently and easily cancerized, and has become one of the hot spots in the research field of large intestine diseases. At present, a FAP prevention and treatment method with ideal curative effect and safety is not available. Current methods of prevention include primarily chemopreventive and surgical prophylactic total colectomy with cyclooxygenase-2 (COX-2) inhibitors. Celecoxib is the only approved chemopreventive drug by FDA in the united states, with an effective rate of only about 30%. The problems of low effective rate, easy polyp recurrence, serious side effect, pharmacogenomics and the like exist in the medicine treatment; the operation can not prevent the polyp canceration of the upper digestive tract and the small intestine, and the problems of serious low life quality and relapse of the patient exist. Therefore, the medicine which can directly inhibit the growth of polyp, has definite curative effect and less side effect is urgently needed to be searched, and has very important significance for the clinical prevention and treatment of FAP, the improvement of the life quality of patients and the reduction of relapse.
Apcmin/+The mouse can spontaneously form multiple adenomas in the intestinal tract due to the mutation of the Apc gene, is widely applied to in vivo research of FAP, and is a good animal model for simulating human FAP. Furthermore, Apcmin/+Mice are also used in the study of various relationships between factors such as various drugs and diets and intestinal tumors.
Cranberry (Cranberry) belongs to Vaccinium of Ericaceae, and is rich in type A Procyanidin (PACs), dietary fiber, ellagitannin, bioflavonoid, and vitamin C, and has excellent antioxidant and free radical scavenging effects. The cranberry can be used for preventing common urinary system infection, reducing incidence of gastric ulcer and gastric cancer, and delaying cardiovascular aging and senile dementia. In recent years, scholars at home and abroad also find that the cranberry has an anti-tumor effect, but the research on preventing and treating FAP is not reported.
Disclosure of Invention
The invention aims to solve the problem that a method for preventing and treating familial adenomatous polyposis with ideal and safe curative effect is lacked at present, and provides application of cranberry freeze-dried powder in preparation of a medicine for preventing and treating familial adenomatous polyposis.
The invention is realized according to the following technical scheme.
An application of cranberry lyophilized powder in preparing medicine for preventing and treating familial adenomatous polyposis is provided.
An edible method of cranberry freeze-dried powder in a medicine for preventing and treating familial adenomatous polyposis comprises the following steps: adding 20-30% cranberry into common diet, and continuously eating for 11-13 weeks.
The present invention obtains the following advantageous effects.
The cranberry freeze-dried powder provided by the invention is used as a dietary supplement which can directly inhibit the growth of polyps, has a definite curative effect and no side effect, and has very important significance for clinical prevention and treatment of FAP, improvement of the life quality of patients and reduction of relapse. The invention provides a safe, effective and economical new method for preventing and treating FAP and sporadic intestinal polyp, and has wide application prospect.
Drawings
FIG. 1 shows that the cranberry lyophilized powder of the present invention reduces APCmin/+Mouse tumor burden plot;
FIG. 2 is a graph of cranberry freeze-dried powder versus APC of the present inventionmin/+The mouse intestinal epithelial cell proliferation plays a role in inhibiting;
fig. 3 is a graph of the inhibitory effect of cranberry lyophilized powder on EGFR signaling pathway activation according to the present invention;
fig. 4 is a graph showing the effect of cranberry freeze-dried powder on inhibiting intestinal inflammation.
Detailed Description
The invention is further explained below with reference to the drawings and examples.
The eating method of the cranberry comprises the following steps: administration of 4 week old APCmin/+Mice were fed 20% cranberries (wt/wt) for 12 weeks.
Cranberry versus APCmin/+Experiment on influence of polyp size and quantity in mice
The classical EGFR pathway mainly comprises a ① mitogen-activated protein kinase pathway (Ras/Raf/MEK/ERK/MAPK pathway), a protein kinase 1 (ERK 1), ERK2, JNK/p38-MAPK and the like which are regulated by activating extracellular signals, phosphorylates cytoplasmic proteins, can also enter a cell nucleus to phosphorylate transcription factors, activates the nuclear AP-1 and mainly mediates cell proliferation and differentiation, and a ② phosphatidylinositol 3 kinase (PI 3K) pathway, wherein a product of PI3K is PIP3 to regulate PDK-1 to cause phosphorylation, further regulates the downstream target proteins such as Caspase-9 and NF-kappa B and the like, and plays an important role in the survival and apoptosis of cells.
The present invention provides 4-week-old APCmin/+Mice were divided into two groups: common diet group (AIN-76A) and cranberry lyophilized powder diet group (AIN-76A mixed with 20% cranberry lyophilized powder). Two groups of mice were fed freely without restriction of diet. Fresh feces were collected at 0 and 12 weeks of the experiment for 16s rrna flora detection. Observing and recording the number, size and distribution of the intestinal adenomas under a microscope. HE staining assesses intestinal tumor case types, immunohistochemistry assesses tumor cell proliferation, TUNEL techniques assesses tumor cell apoptosis. The level of intestinal inflammation was assessed by RT-PCR. Immunohistochemistry and WESTERN BLOT assessed activation of the EGFR signaling pathway. The levels of short chain fatty acids SCFAs were determined by gas chromatography of ileocecal intestinal contents.
The invention passes the pair Apcmin/+The intervention discovery that the mice are fed with cranberry freeze-dried powder diet comprises the following steps: the cranberry diet can reduce the total number of intestinal polyps by 33.1 percent, remarkably reduce the size of the intestinal polyps, promote apoptosis while inhibiting the proliferation of tumor cells, inhibit the activation of EGFR and Akt and lower the expression levels of COX-2 and PGE2 in small intestines. Meanwhile, the cranberry can obviously reduce the expression of intestinal inflammatory cytokines (IL-6, IL-9, IFN-gamma and IL-17A), up-regulate the expression level of anti-inflammatory factors (IL-4 and IL-10) (see figures 1-4) and obviously improve the level of short-chain fatty acids SCFAs (acetic acid, propionic acid and butyric acid) in the ileocecal part (see table 1). Small sample clinical research shows that cranberry can inhibit recurrence of FAP patient after endoscopic resection of rectal polyp.
Claims (1)
1. The application of the cranberry freeze-dried powder in preparing the medicine for preventing and treating familial adenomatous polyposis is characterized in that: the addition amount of the cranberry freeze-dried powder is 20%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710089659.2A CN106822217B (en) | 2017-02-20 | 2017-02-20 | Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710089659.2A CN106822217B (en) | 2017-02-20 | 2017-02-20 | Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106822217A CN106822217A (en) | 2017-06-13 |
| CN106822217B true CN106822217B (en) | 2020-05-05 |
Family
ID=59127967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710089659.2A Active CN106822217B (en) | 2017-02-20 | 2017-02-20 | Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822217B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101951900A (en) * | 2008-02-22 | 2011-01-19 | Cm&D制药有限公司 | Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| CN102058590A (en) * | 2010-12-27 | 2011-05-18 | 天津医科大学总医院 | Application of berberine to preparing drug for preventing and treating familial adenomatous polyp |
| CN105687422A (en) * | 2016-03-02 | 2016-06-22 | 深圳福山生物科技有限公司 | Raspberry composition and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130045203A1 (en) * | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
-
2017
- 2017-02-20 CN CN201710089659.2A patent/CN106822217B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101951900A (en) * | 2008-02-22 | 2011-01-19 | Cm&D制药有限公司 | Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| CN102058590A (en) * | 2010-12-27 | 2011-05-18 | 天津医科大学总医院 | Application of berberine to preparing drug for preventing and treating familial adenomatous polyp |
| CN105687422A (en) * | 2016-03-02 | 2016-06-22 | 深圳福山生物科技有限公司 | Raspberry composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| COX-2在直肠腺瘤性息肉与癌组织中的表达及意义;廖湘鲁等;《中国癌症杂志》;20031231;第13卷(第3期);第250-252页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106822217A (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Quercetin improves immune function in Arbor Acre broilers through activation of NF-κB signaling pathway | |
| Zhu et al. | Flaxseed oil attenuates intestinal damage and inflammation by regulating necroptosis and TLR4/NOD signaling pathways following lipopolysaccharide challenge in a piglet model | |
| Hur et al. | Review of natural products actions on cytokines in inflammatory bowel disease | |
| Li et al. | Dietary supplementation with Clostridium butyricum helps to improve the intestinal barrier function of weaned piglets challenged with enterotoxigenic Escherichia coli K88 | |
| Kundu et al. | Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals | |
| Vuong et al. | Role of a polyphenol-enriched preparation on chemoprevention of mammary carcinoma through cancer stem cells and inflammatory pathways modulation | |
| Zhang et al. | Effects of Glycyrrhiza polysaccharide in diet on growth performance, serum antioxidant capacity, and biochemistry of broilers | |
| Liu et al. | Dietary addition of Artemisia argyi reduces diarrhea and modulates the gut immune function without affecting growth performances of rabbits after weaning | |
| KR101244964B1 (en) | Use of dendropanax morbifera extracts for controlling a 15-hydroxyprostaglandin dehydrogenase and pge2 activity | |
| Jian et al. | Dietary valine ameliorated gut health and accelerated the development of nonalcoholic fatty liver disease of laying hens | |
| Zhao et al. | Short-chain fructo-oligosaccharides enhances intestinal barrier function by attenuating mucosa inflammation and altering colonic microbiota composition of weaning piglets | |
| CN111436601A (en) | Special clinical nutrition formula for pancreatic cancer and preparation thereof | |
| Massimini et al. | Polyphenols and cannabidiol modulate transcriptional regulation of Th1/Th2 inflammatory genes related to canine atopic dermatitis | |
| AU2021246790B9 (en) | Anti-tumor composition containing rare ginsenosides Rk2, CK, and PPT | |
| Li et al. | Oral administration of Lactobacillus delbrueckii during the suckling period improves intestinal integrity after weaning in piglets | |
| Cheng et al. | The promising effects of astaxanthin on lung diseases | |
| Zhang et al. | Influences of dietary Eucommia ulmoides leaf extract on the hepatic lipid metabolism, inflammation response, intestinal antioxidant capacity, intestinal microbiota, and disease resistance of the channel catfish (Ictalurus punctatus) | |
| Zhong et al. | DL-methionine and DL-methionyl-DL-methionine increase intestinal development and activate Wnt/β-catenin signaling activity in domestic pigeons (Columba livia) | |
| CN111870609A (en) | Intestinal flora regulator and application thereof | |
| Yan et al. | Improvement of sea buckthorn (Hippophae rhamnoides L.) flavonoids on the antioxidant and immune performance of Yellow River carp (Cyprinus carpio L.) fed high-carbohydrate diet | |
| Roglia et al. | Exogenous miRNAs from Moringa oleifera Lam. recover a dysregulated lipid metabolism | |
| CN106822217B (en) | Application of cranberry freeze-dried powder in preparation of medicine for preventing and treating familial adenomatous polyposis | |
| Xing et al. | Artemisia ordosica polysaccharide ameliorated LPS-induced growth inhibition and intestinal injury in broilers through enhancing immune-regulation and antioxidant capacity | |
| Fu et al. | 4-octyl itaconate supplementation relieves soybean diet-induced liver inflammation and glycolipid metabolic disorders by activating the nrf2-pparγ Pathway in juvenile gibel carp | |
| Sun et al. | Effects of dietary Senecio scandens buch-ham extracts on growth performance, plasma biochemical, histology and the expression of immune-related genes in hybrid grouper (Epinephelus lanceolatus♂× Epinephelus fuscoguttatus♀) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |